A method for treating motor neuron diseases, comprising intrathecally administering to an individual in need thereof an effective amount of a composition comprising mesenchymal stem cells, wherein the motor neuron disease is amyotrophic lateral sclerosis (“ALS”), progressive bulbar palsy (“PBP”), primary lateral sclerosis (“PLS”), or progressive muscular atrophy (“PMA”), wherein the mesenchymal stem cells express CD105 (SH2), CD29, CD44, and CD73 at 95% or more, express CD166 at 90% or more, express CD34, CD45, and HLA-DR at 5% or less, and express CDIa, CD14, CD31, and CD80 at 10% or less, and wherein mesenchymal stem cells are contained in an amount of 1×104 to 5×106 cells/ml in the composition, and wherein the individual exhibits enhanced motor ability.